| Aug 14 |
Verrica Pharmaceuticals Non-GAAP EPS of -$0.31 beats by $0.09, revenue of $5.12M
|
| Aug 14 |
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
|
| Aug 14 |
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
|
| Aug 6 |
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
|
| Jul 29 |
3 High Insider Ownership US Stocks With Up To 52% Revenue Growth
|
| Jul 15 |
7 Short-Squeeze Stocks That Could Beat Down the Bears
|
| Jul 10 |
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
|
| Jul 1 |
Verrica Pharmaceuticals Settles Cantharidin-Related Lawsuit With Dormer Labs
|
| Jul 1 |
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
|
| Jun 28 |
High Insider Ownership Growth Stocks On US Exchange For June 2024
|
